Can an Immune-Calming drug tame Behçet's Flare-Ups?
NCT ID NCT02648581
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This small study tested ustekinumab, a drug that calms the immune system, in 16 adults with Behçet disease. The goal was to see if it could reduce mouth ulcers and eye inflammation. The trial is complete, but because it's early and small, we don't yet know if the drug will become a standard treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ustekinumab (a drug that calms the immune system)
- What this could lead to
- If it works, this could point toward a new treatment option for Behçet disease, reducing painful ulcers and eye inflammation.
- What could go wrong
- This is a very small, early-phase trial with only 16 people, so results may not apply to everyone. The drug may not work or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BEHÇET DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Cochin, Department of Internal Medicine, National Reference Center for Autoimmune and Systemic Diseases
Paris, Paris, 75014, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immune clues in the blood may foretell heart trouble
- Massive biobank launches to unlock secrets of chronic inflammation
- AI reads your gut scans to spot disease without a scope
- Can a quick skin scan reveal hidden inflammation in arthritis?
- Shingles vaccine trial aims to protect vulnerable patients
- New hope for kids with painful mouth sores: drug trial launches